Maxim Group Reiterates Buy On StemCells Following Initiation Of Pathway Study
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on StemCells Inc (NASDAQ:STEM) with a $5 price target, as the company announced the launch of the Pathway study, a Phase II proof of concept clinical trial using its HuCNS-SC platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI). The Pathway Phase II clinical trial will be a randomized, controlled, singleblind study with a primary endpoint of change from baseline in ISNCSCI upper extremity motor scores. Patients will be followed for a period of twelve months post enrollment.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 8.4% and a 49.1% success rate. Kolbert has an -20.1% average return when recommending STEM, and is ranked #361 out of 3318 analysts.